PBYI Stock Analysis: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$6.81
0.33 (5.09%)
▲
5d:
+5.91%
30d:
+14.45%
90d:
+24.73%
HOLD
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 26, 2026
23d
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PBYI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PBYI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.73
Based on -8.2% avg growth
INTRINSIC VALUE TODAY
$2.31
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $6.81, which is considered extended relative to its 30-day fair value range of $6.01 to $6.60. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.8) compared to its historical average (10.6). At these levels, the market is pricing in 3.4% annual earnings growth.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $6.26, while resistance sits at $7.21. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $6.26, while resistance sits at $7.21. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$6.01 -
$6.60
Company Quality Score
58/100
(HOLD)
Options IV Signal
25th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
59.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 25th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BEARISH: Trading 22.8% above Wall St target ($5.00)
- BULLISH: Expecting earnings turnaround to 3.4% growth with -32.4% revenue growth
Fair Price Analysis
30-Day Fair Range
$6.01 -
$6.60
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.62
(9.1%)
Support & Resistance Levels
Support Level
$6.26
Resistance Level
$7.21
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
11.78
Wall Street Target
$5.00
(-22.8%)
Revenue Growth (YoY)
-32.4%
Earnings Growth (YoY)
-58.5%
Profit Margin
17.4%
Valuation Premium vs History
+3.4% premium
PE vs Historical
11.8 vs 10.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.4%
(market-implied from PE analysis)
1-Year Target
$6.70
(+3%)
2-Year Target
$6.93
(+7%)
3-Year Target
$7.16
(+11%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$6.45
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -20.3%)
$8.94
(+38%)
Base:
(SPY PE: 11.8, Growth: -20.3%)
$4.72
(-27%)
Bear:
(PE: 10.0, Growth: -20.3%)
$4.02
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 8.54 | Current EPS (TTM): $0.74
Bull Case
$5.17
(-20%)
Analyst growth -25.7%, PE expands to 9.4
Base Case
$4.70
(-28%)
Market implied -25.7%, PE stable at 8.5
Bear Case
$4.30
(-34%)
Severe decline -20.0%, PE contracts to 7.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 02, 2026 3:18 PM ET
Data refreshes hourly during market hours. Next update: 4:18 PM
Data refreshes hourly during market hours. Next update: 4:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 55 HOLD |
